Pre-Clinical Study for Regenerative Commercial-Sized Breast Implants Announced 

The advancement of regenerative medicine continues to grow at a rapid pace. CollPlant Biotechnologies and Stratasys Ltd. announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on Stratasys Origin 3D printer. 

The collaboration is currently focused on the development of a bioprinting solution for CollPlant’s breast implants, in addition to finding solutions to scale-up the implant’s fabrication process. 

A press release explained the study is intended to test the ability of the implants to promote growth of natural breast tissue and completely degrade over time. 

CollPlant’s breast implants have been designed to regenerate a person’s natural breast tissue without eliciting an immune response and could provide a revolutionary alternative for both reconstructive and aesthetic procedures, which represents a significant portion of the overall $3 billion addressable breast implant market. 

“This pre-clinical study marks a significant step forward in our effort to provide patients with care using regenerative medicine instead of traditional implants,” Stratasys CEO Dr. Yoav Zeif said. “CollPlant’s work is truly inspiring, and our collaboration exemplifies how Stratasys partners with customers to push the timeline and the boundaries of innovation. Together, we are driven by a shared mission to challenge the status quo and find new ways to improve lives and advance healthcare.” 

CEO of CollPlant Yehiel Tal expressed the company is “extremely happy about the progress we’ve made with our breast implants program.” 

Adding, “With Stratasys’ successful achievement to develop a printer that enables us to print a commercial-size implant with high resolution and optimal physical properties. The combined pioneering technologies of both companies is expected to streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants. We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer, thereby significantly improving patient outcomes.”

Since announcing the collaboration in April 2023, Stratasys has adapted the Origin printer to print the regenerative implants, and CollPlant successfully managed to 3D-print them at 200ccs.

CollPlant is expecting to have initial results from the study in the first half of 2025.